The stock, which made its debut at Rs 420 per share on NSE and Rs 412 per share on the Bombay Stock Exchange (BSE) in ...

Pagaya's new products and risk diversification boost growth potential. Find out why PGY stock is a strong buy with 253% ...

SRIVARU Holding Limited (OTC: SVUHF) (“SRIVARU” or the “Company”), has been made aware of a legal claim against the Company (“Sabby”) in the Supreme Court of the State of New York, Index No.

Uniti Group Inc. remains a strong buy after Q4 earnings. It has growth, debt reduction, AI focus, and potential returns of up ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

Bluebird Bio (BLUE) announced that it has entered into a definitive agreement to be acquired by funds managed by Carlyle (CG) and SK Capital ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

The company might buy the shares directly or offer shareholders the option of tendering their shares at a fixed price. Share repurchases automatically increase the earnings per share (EPS ...